CytRx (CYTR) Files Response to FDA On Partial Clinical Hold On Phase 2b Arimoclomol ALS Trial
More News related to CYTR
- CytRx Announces Publication of Paper Stating that Chaperone Amplification Represents a 'Significant Strategy' in Anti-aging Pharmaceutical Design
- CytRx Fortifies Executive Suite with Addition of Chief Medical Officer
- CytRx (CYTR) and Cephalon (CEPH) Oncology Therapies to be Evaluated as Treatment for Relapsed Acute Promyelocytic Leukemia
- CytRx and Cephalon Oncology Therapies to be Evaluated as Treatment for Relapsed Acute Promyelocytic Leukemia
- Morning Movers 9/10: DVAX, DARA, GNBT, XRTX, NCS Higher; PLAB, SEH, NAV Lower
CytRx Corporation (NASDAQ: CYTR) filed a report with the FDA in response to the Agency's partial clinical hold on the Company’s Phase 2b efficacy clinical trial with its molecular chaperone regulator drug candidate arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).
CEO Steven A. Kriegsman said, "We have been working closely with the FDA throughout this process and we are confident that the information included in this report, including results from a detailed animal toxicology study, sufficiently addresses the Agency's concerns."
Related Categories
FDAStocks Mentioned
+0.05Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
